Moderately Agressive Portfolio

By Rick Walter

The end of the year is fast approaching and its time to start thinking about doing some investment house-cleaning. Take a look at the total returns of our Moderately Aggressive portfolio posted today. This portfolio has performed very well since April '09 of this year and I expect it to continue to rack up gains as the economy continues to improve. Now, if I were a smart investor I would wait for prices to come back down a little bit before I made a move but the risks are that quality assets, and most fund managers know what they are, could get a bit pricier. Finally, its the beginning of earnings reporting for the third quarter of the year, so we should begin to get a clearer picture of the financial health of many companies. We should keep in mind though that many companies normally report not-so-stellar performances in the third quarter of the year.

Comments

Portfolio Update

By Rick Walter I have posted a new Biotechnology portfolio . It's total return as of November 25, 2009 is 3.4%. However, to download and use it you will have to subscribe to the portfolio, of course. On an important note, I consider each portfolio to be well diversified in its particular sector but I've recently decided to add stock futures and options positions to each portfolio which will increase each portfolio's return but lower the risks going forward.

Morning Update

By Rick Walter Still working on putting together a strong biotech portfolio. Here is a good general article on the state of the biotech industry that was posted yesterday on the online Wall Street Journal's site- Biotech Stocks Hot Right Now, Ho-Hum in the Long Run.

Biotech Pump and Dump

By Rick Walter Building a good Biotechnology portfolio has turned out to be a bit of a task. I have one on the table, but feel that it's a little too aggressive and risky, especially for today's market. Funding for most Biotech ventures- old or new, have either dried up or have been put on hold. This portfolio that I am building is too much of a pure Biotech play. It would be feast or famine on the returns. Let me explain. I remember when I was a young broker, I worked for this small outfit in Florida where the office manager and a few other brokers, including myself, would get all pumped up over a stock called Celi. I believe that the stock is now trading on the Amex as (Cel-Sci: CVM ). Well the stock was always on the verge of getting approval for some phase of cancer treatment therapy. Whenever the company released news, we would run the stock up as high as the market makers would let us run it- ($1.30 to $2.30 per share) before we banged it back down to previous lows of .30...

All Things ETF

Search This Blog